Valuation: Compass Therapeutics, Inc.

Market Cap 349M 303M 282M 260M 490M 33.35B 498M 3.34B 1.31B 16.57B 1.31B 1.28B 55.71B P/E 2026 *
-4.45x
P/E 2027 * -4.18x
Enterprise Value 199M 173M 161M 148M 279M 19.03B 284M 1.9B 745M 9.45B 749M 732M 31.79B EV / Sales 2026 *
-96.9x
EV / Sales 2027 * 8.6x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 27/05/2024
Director of Finance/CFO 54 08/12/2024
Chief Tech/Sci/R&D Officer 50 31/12/2025
Director TitleAgeSince
Director/Board Member 65 31/12/2013
Director/Board Member 64 31/12/2014
Chairman 61 31/12/2014
Change 5-day change 1-year change 3-year change Capi.($)
-10.80%+32.67% - - 349M
-0.81%-0.33%+27.15%+81.12% 55.6B
-3.74%-1.56%+45.14%+64.45% 55.2B
-0.11%+1.11%-16.71%-13.56% 23.51B
-1.58%-4.83%-3.34%+375.36% 22.35B
+0.79%-2.68%+12.50%-12.70% 20.6B
-1.23%-3.51%+25.70%-31.88% 17.45B
-0.46%-6.96%+22.02%+515.48% 15.16B
+1.16%+1.80%+51.52%+181.96% 13.91B
-5.09%-13.14%+151.85%+272.20% 13.74B
Average -2.95%-2.32%+35.09%+159.16% 26.39B
Weighted average by Cap. -2.11%-1.00%+31.05%+123.81%

Financials

2026 *2027 *
Net sales -2.06M -1.79M -1.66M -1.53M -2.88M -196M -2.93M -19.64M -7.69M -97.54M -7.73M -7.56M -328M 25.27M 21.95M 20.38M 18.8M 35.41M 2.41B 36.05M 241M 94.48M 1.2B 94.89M 92.82M 4.03B
Net income -82.44M -71.6M -66.49M -61.32M -116M -7.87B -118M -787M -308M -3.91B -310M -303M -13.14B -89.57M -77.8M -72.25M -66.63M -126M -8.55B -128M -855M -335M -4.25B -336M -329M -14.28B
Net Debt -150M -130M -121M -112M -210M -14.32B -214M -1.43B -561M -7.11B -563M -551M -23.92B -132M -115M -106M -98.19M -185M -12.6B -188M -1.26B -494M -6.26B -496M -485M -21.05B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
1.940USD
Average target price
8.500USD
Spread / Average Target
+338.14%

Quarterly revenue - Rate of surprise